Evidence map›Paper›PMID 40163255›Full record

ReviewDiscover oncology2025

Research progress on the signaling pathway mechanism of terpenoids against breast cancer.

Sheng-Nan Tu, Fen Hu, Juan Zhang, Haifeng Cai, Junquan Yang

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sheng-Nan TuSchool of Clinical Medicine, North China University of Science and Technology, Tangshan, 063210, China.
Fen HuCollege of Life Sciences, North China University of Science and Technology, Tangshan, 063210, China.
Juan ZhangSecond Department of Mammary Gland, Tangshan People's Hospital, Tangshan, 063000, China.
Haifeng CaiSecond Department of Mammary Gland, Tangshan People's Hospital, Tangshan, 063000, China. 13303050005@163.com.
Junquan YangSchool of Clinical Medicine, North China University of Science and Technology, Tangshan, 063210, China. 13313059092@163.com.

Funding

Wu Jieping Medical Foundation Clinical Research Special Fund 320.6750.17209
6 · The paper itself

Abstract

Breast cancer is the most common malignant tumor in women worldwide. Current treatments include chemotherapy, hormone therapy, radiotherapy and surgery. Terpenoids have great anti-cancer potential due to their anti-inflammatory, antioxidant, anti-tumor, antiviral and other biological activities. They have become the central drug for the prevention and treatment of breast cancer. However, their low bioavailability and stability are urgent issues that need to be addressed. This article aims to sort out the mechanism of action of terpenoids in the treatment of breast cancer. By reviewing different signal transduction pathways, it is hoped that new ideas for the joint action of multiple pathways and multiple targets will be provided, and a theoretical basis will be provided for improving basic research and clinical treatment of breast cancer.

Indexed as

Breast cancerReviewSignal passageTerpenoids

Identifiers

PMID40163255
PMCPMC11958888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.